Clinical Practice Guideline Updated for Migraine, Tension-Type Headache

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 29, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Oct. 29, 2024 -- In a clinical practice guideline (CPG) issued by the U.S. Department of Veterans Affairs and U.S. Department of Defense and published online Oct. 29 in the Annals of Internal Medicine, updated recommendations are presented for the management of migraine and tension-type headache (TTH).

Noting that the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense CPG for the management of headache was revised in 2023 in accordance with rapidly expanding and evolving evidence, Jason J. Sico, M.D., from the VA Connecticut Healthcare System in West Haven, and colleagues reviewed the recommendations relevant to primary care clinicians for treatment and prevention of migraine and TTH. Twelve key questions were developed, which guided a systematic search using predefined inclusion and exclusion criteria.

Fifty-two recommendations on evaluation, pharmacotherapy, invasive interventions, and nonpharmacologic interventions for selected primary and secondary headache disorders were included in the revised CPG. Newer calcitonin gene-related peptide (CGRP) inhibitors (gepants) are options for acute migraine treatment in addition to triptans and aspirin-acetaminophen-caffeine. Angiotensin-receptor blockers, lisinopril, magnesium, topiramate, valproate, memantine, the newer CGRP monoclonal antibodies, and atogepant can be used to prevent episodic migraine. For prevention of chronic migraine, but not episodic migraine, abobotulinumtoxinA can be used. Gabapentin is not recommended for episodic migraine prevention. Treatment of TTH can include ibuprofen (400 mg) and acetaminophen (1,000 mg); for preventing chronic TTH, amitriptyline can be used. Management of TTH and migraines can also include physical therapy or aerobic exercise.

"Clinicians should work with their patients in crafting treatment plans that account for headache type or types, comorbid conditions, and values and preferences," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-30 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords